Want to see IN:TARSONS full AI Analyst Report?
Top Page
Tarsons Products Limited
(TARSONS)
Select Model
Select Model
Rating:47Neutral
Price Target:
₹287.00
▼(-8.17% Downside)
Action:Reiterated
Date:09/22/26
The score is held back primarily by weakening profitability, rising debt, and persistently negative free cash flow, alongside a very high P/E valuation. Technicals are moderately supportive with price above major moving averages, but mixed momentum (negative MACD) limits the uplift.
Positive Factors
Diversified laboratory consumables platform
The company serves research, diagnostics, healthcare, pharmaceutical, and academic laboratories with a broad portfolio of single-use and reusable products. This diversified application base can support recurring demand and reduce reliance on any single customer segment over the next several quarters.
Negative Factors
Weakened profitability
Earnings power has deteriorated materially from the stronger 2021–2023 period, with 2026 operating profit notably below prior years despite higher revenue. Persistently weaker margins could limit reinvestment capacity and make future growth less effective at translating into shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified laboratory consumables platform
The company serves research, diagnostics, healthcare, pharmaceutical, and academic laboratories with a broad portfolio of single-use and reusable products. This diversified application base can support recurring demand and reduce reliance on any single customer segment over the next several quarters.
Read all positive factors
Tarsons Products Limited (TARSONS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹15.52B
Dividend Yield0.42%
Average Volume (3M)13.15K
Price to Earnings (P/E)139.2
Beta (1Y)1.02
Revenue Growth10.63%
EPS Growth-59.63%
CountryIN
Employees1,108
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)2.09
Shares Outstanding53,206,280
10 Day Avg. Volume4,403
30 Day Avg. Volume13,148
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)1.51
Price to Sales (P/S)2.27
P/FCF Ratio-134.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.7
Revenue Forecast (FY)₹4.88B
Tarsons Products Limited Business Overview & Revenue Model
Company Description
Established in 1983 and headquartered in Kolkata, India, Tarsons Products Limited specializes in the global manufacturing and distribution of plastic laboratory supplies and scientific instruments. The company's diverse product portfolio features ...
Tarsons Products Limited Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
55
Neutral
Cash Flow
42
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.41B | 4.23B | 3.92B | 2.96B | 2.83B | 3.01B |
| Gross Profit | 1.11B | 1.12B | 1.35B | 985.42M | 1.25B | 1.49B |
| EBITDA | 1.32B | 1.18B | 1.27B | 1.11B | 1.42B | 1.61B |
| Net Income | 110.95M | 143.22M | 297.70M | 426.40M | 807.14M | 1.01B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 11.86B | 10.80B | 9.72B | 7.26B | 5.44B |
| Cash, Cash Equivalents and Short-Term Investments | 252.56M | 252.56M | 256.52M | 226.11M | 590.58M | 774.42M |
| Total Debt | 0.00 | 3.93B | 3.39B | 2.69B | 1.11B | 216.65M |
| Total Liabilities | -6.35B | 5.51B | 4.50B | 3.59B | 1.56B | 543.96M |
| Stockholders Equity | 6.35B | 6.35B | 6.30B | 6.13B | 5.69B | 4.90B |
Cash Flow | ||||||
| Free Cash Flow | -267.75M | -71.03M | -550.87M | -816.28M | -1.14B | -485.02M |
| Operating Cash Flow | 444.51M | 1.18B | 966.20M | 1.03B | 755.99M | 834.67M |
| Investing Cash Flow | -783.05M | -1.30B | -1.47B | -2.85B | -1.79B | -1.38B |
| Financing Cash Flow | 321.34M | 89.33M | 578.12M | 1.36B | 845.61M | 1.30B |
Tarsons Products Limited Technical Analysis
Negative
312.55
Price Trends
325.78
Negative
307.45
Negative
255.41
Positive
Market Momentum
-8.02
Positive
36.90
Neutral
20.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TARSONS, the sentiment is Negative. The current price of 312.55 is below the 20-day moving average (MA) of 319.04, below the 50-day MA of 325.78, and above the 200-day MA of 255.41, indicating a neutral trend. The MACD of -8.02 indicates Positive momentum. The RSI at 36.90 is Neutral, neither overbought nor oversold. The STOCH value of 20.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:TARSONS.
Tarsons Products Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₹21.67B | 27.15 | ― | 0.41% | 14.22% | 7.17% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₹146.76B | 46.62 | ― | 0.24% | 18.31% | -12.86% | |
50 Neutral | ₹7.32B | 166.21 | ― | 0.15% | 7.55% | -57.19% | |
47 Neutral | ₹15.52B | 139.23 | ― | 0.42% | 10.63% | -59.63% | |
46 Neutral | ₹1.26B | -8.65 | ― | ― | -1.32% | 51.41% | |
45 Neutral | ₹16.20B | 54.14 | ― | 0.20% | 195.95% | 1526.86% |
* General Sector Average
IN:TARSONS
Tarsons Products Limited
291.75
2.40
0.83%
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
58.36
-11.14
-16.03%
IN:POLYMED
Poly Medicure Limited
1,447.90
-546.41
-27.40%
IN:VIMTALABS
Vimta Labs Limited
484.85
-237.74
-32.90%
IN:ZIMLAB
Zim Laboratories Ltd.
136.45
62.99
85.75%
IN:FISCHER
Fischer Medical Ventures Ltd
24.75
-92.72
-78.93%
Tarsons Products Limited Corporate Events
Tarsons Products Convenes 43rd AGM via Virtual Platform with Strong Shareholder Turnout
Sep 24, 2026
Tarsons Products Limited held its 43rd Annual General Meeting on September 24, 2026, via video conferencing in compliance with MCA and SEBI circulars and applicable listing regulations. The meeting saw participation from key members of the board, ...
Tarsons Schedules Virtual Analyst Meet with Arihant Capital
Sep 24, 2026
Tarsons Products Limited has notified stock exchanges that its officials will participate in a virtual group meeting hosted by Arihant Capital on September 30, 2026, between 5:00 p.m. and 6:00 p.m. IST. The interaction is aimed at analysts and ins...
Tarsons Clarifies Share Volume Surge, Affirms Full Regulatory Compliance
Sep 21, 2026
Tarsons Products Limited, an ISO-certified manufacturer in the laboratory and life-sciences consumables space, is headquartered in Kolkata and listed on the National Stock Exchange of India under the symbol TARSONS. The company serves institutiona...
Tarsons Products Publishes Q1 FY27 Investor Presentation for Market Disclosure
Aug 10, 2026
Tarsons Products Limited has released an investor presentation detailing its financial results for the quarter ended June 30, 2026, and submitted the same to both the BSE and NSE in line with SEBI disclosure regulations. The document, prepared und...
Tarsons Posts Q1 FY27 Results and Sets Date for 43rd AGM
Aug 10, 2026
Tarsons Products Limited reported its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, as approved by its board of directors in a meeting held on August 10, 2026. The results, accompanied by a limited re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.